Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Luke Adam Monteagudo, Aaron Boothby, Elie Gertner, Luke Adam Monteagudo, Aaron Boothby, Elie Gertner

Abstract

Objective: The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis or macrophage activation syndrome (MAS).

Methods: A retrospective chart review of five patients treated at Regions Hospital from 2016 to 2019 was conducted. Demographic, clinical, and laboratory characteristics and outcomes were recorded.

Results: Continuous IV anakinra infusions up to 2400 mg/d resulted in rapid serologic, then clinical response in 4 of 5 severely ill patients who were refractory to all other therapies, including subcutaneous anakinra. Subsequently, 3 of 5 patients have been maintained on anakinra or canakinumab, with no recurrence of MAS.

Conclusion: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease who have a cytokine storm presentation.

© 2020 The Authors. ACR Open Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

References

    1. Hayden A, Park S, Guistini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev 2016;30:411–20.
    1. Allen CE, McClain KL. Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program 2015;2015:177–82.
    1. Janka G. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012;63:233–46.
    1. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2016;68:566–76.
    1. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic‐onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003;142:292–6.
    1. Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol 2018;10:117–28.
    1. Tristano AG. Macrophage activation syndrome: a frequent but under‐diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008;14:RA27–36.
    1. Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014;66:3160–9.
    1. Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford) 2019;58:5–17.
    1. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol 2019;10:119.
    1. Bracaglia C, Prencipe G, de Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J 2017;15:5.
    1. Li X, Qu B, Nie Y, Zhu G, Li W, Mu F. Clinical features of macrophage activation syndrome in the adult northern Chinese population. Lupus 2014;23:785–92.
    1. Stéphan JL, Koné‐Paut I, Galambrun C, Mouy R, Bader‐Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford) 2001;40:1285–92.
    1. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine‐directed therapies. Annu Rev Med 2015;66:145–59.
    1. Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al, and the HLH Study Group of the Histiocyte Society . HLH‐94: a treatment protocol for hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 1997;28:342–7.
    1. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH‐2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.
    1. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014;89:484–92.
    1. Park HS, Kim DY, Lee JH, Kim SD, Park YH, Lee JS, et al. Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis from causes other than lymphoma: an analysis of treatment outcome and prognostic factors. Ann Hematol 2012;91:897–904.
    1. Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008;4:615–20.
    1. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis‐associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 2011;17:23–7.
    1. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease‐associated macrophage activation syndrome with interleukin‐1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011;50:417–9.
    1. Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020;72:326–34.
    1. Divithotawela C, Garrett P, Westall G, Bhaskar B, Tol M, Chambers DC. Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor: anakinra. Respirol Case Rep 2016;4:4–6.
    1. Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med 2019;34:723–31.
    1. Ocon AJ, Bhatt BD, Miller C, Peredo RA. Safe usage of anakinra and dexamethasone to treat refractory hemophagocytic lymphohistiocytosis secondary to acute disseminated histoplasmosis in a patient with HIV/AIDS. BMJ Case Rep 2017;2017:bcr‐2017‐221264.
    1. Nusshag C, Morath C, Zeier M, Weigand MA, Merle U, Brenner T. Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis: a case report and review of the literature. Medicine (Baltimore) 2017;96:e9283.
    1. Hardman SJ, Tukur G, Waruiru C. Enterovirus‐associated HLH: addition of anakinra to IVIG and corticosteroids. J Clin Immunol 2019;39:373–5.
    1. Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003;74:85–94.
    1. Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long‐term results of the cooperative HLH‐2004 study. Blood 2017;130:2728–38.
    1. Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long‐term results of the HLH‐94 treatment protocol. Blood 2011;118:4577–84.
    1. Ramos‐Casals M, Brito‐Zerón P, López‐Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome [published erratum appears in Lancet 2014;383:1464]. Lancet 2014;383:1503–16.
    1. Fukaya S, Yasuda S, Hashimoto T, Oku K, Kataoka H, Horita T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases. Rheumatology (Oxford) 2008;47:1686–91.
    1. Moore C, Ormseth M, Fuchs H. Causes and significance of markedly elevated serum ferritin levels in an academic medical center. J Clin Rheumatol 2013;19:324–8.
    1. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 2015;125:2908–14.
    1. Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL‐1 and IL‐6 inhibition. Adolesc Health Med Ther 2017;8:125–35.
    1. Nikiforow S, Berliner N. To, “lump” or to “split” in macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020;72:206–9.
    1. Ghuman A, Kumar K, Singh A. Intravenous anakinra treatment in a rare case of macrophage activation syndrome presenting as fulminant liver failure. Rheumatol Adv Pract 2018;2 Suppl 1:rky034.049.
    1. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin‐1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275–81.
    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する